AzTrials
AzTrials

Ischemia-Reperfusion InjuryRIPCNCT07487220

Non-invasive Remote Ischemic PreConditioning (RIPC) in Free Flaps for Breast Reconstruction

A study testing Remote ischemic preconditiong in people with Ischemia-Reperfusion Injury and Free Flap, run by Ruhr University of Bochum at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This prospective randomized clinical study investigates the effects of Remote Ischemic Conditioning (RIC) on tissue perfusion and ischemia-reperfusion injury in patients undergoing free flap reconstruction in reconstructive microsurgery. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Remote ischemic preconditiong
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
49 participants
Where
1 siteGermany
Study dates
1 Apr 2021to 31 Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years
  • Patients undergoing free flap reconstruction surgery for reconstruction of body surface defects
  • Treatment at the Department of Plastic Surgery, BG Universitätsklinikum Bergmannsheil Bochum
  • Ability to understand the study procedures
  • Written informed consent to participate in the study

Who cannot join

  • Refusal or inability to provide informed consent
  • Contraindications to regional nerve block or perioperative procedures required for the study
  • Any condition that prevents participation according to investigator judgment

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • BG University Clinic Bergmannsheil

    Bochum, North Rhine-Westphalia, 44789

Other trials in Germany

About this study

Official title: Non-invasive Remote Ischemic PreConditioning in Free Flaps for Breast Reconstruction

This prospective randomized clinical study investigates the effects of Remote Ischemic Conditioning (RIC) on tissue perfusion and ischemia-reperfusion injury in patients undergoing free flap reconstruction in reconstructive microsurgery. RIC is a non-invasive conditioning technique using cyclic ischemia and reperfusion applied to an extremity, which may enhance microcirculation and induce tissue protection.

The study aims to evaluate whether preoperative RIC improves postoperative flap perfusion, reduces ischemia-reperfusion- related tissue damage, and enhances clinical outcomes such as flap survival, wound healing, and need for revision surgery. Patients undergoing free flap procedures will be randomized to receive either preoperative RIC (immediate or delayed) or no conditioning.

Additional analyses include continuous postoperative monitoring of microcirculation, histological and molecular assessment of tissue samples, and evaluation of circulating biomarkers associated with tissue protection.

Read the detailed description

Background Free flap reconstruction represents the gold standard for complex soft tissue defects arising from tumor resection, trauma, or chronic wounds. Despite refinements in microsurgical technique and perioperative management, flap-related complications, including partial necrosis, wound healing disorders, and total flap loss, continue to occur at clinically meaningful rates. The underlying pathophysiology involves obligatory ischemia during flap harvest and transfer, followed by reperfusion upon anastomosis completion. This ischemia-reperfusion (I/R) sequence triggers a cascade of oxidative stress, endothelial dysfunction, inflammatory activation, and microcirculatory failure that can ultimately compromise tissue viability.

Current intraoperative strategies to mitigate I/R injury remain limited, and no pharmacological or mechanical intervention has been established as standard of care in this context.

Scientific Rationale for Remote Ischemic Conditioning Remote Ischemic Conditioning (RIC) exploits the endogenous capacity of biological tissue to develop tolerance to ischemic stress when exposed to brief, non-lethal cycles of ischemia and reperfusion at a site distant from the target organ. Originally described in cardiac surgery, RIC has since been investigated across a range of ischemia-sensitive tissues and clinical scenarios. Proposed mechanisms include neuronal and humoral signaling pathways that activate cytoprotective programs, such as upregulation of heat shock proteins, modulation of the RISK (Reperfusion Injury Salvage Kinase) pathway, suppression of mitochondrial permeability transition pore opening, and attenuation of neutrophil-mediated endothelial injury.

Preclinical models of pedicled and free flaps have demonstrated improved perfusion, reduced apoptosis, and enhanced flap survival following RIC. However, these findings have not yet been translated into a prospective randomized clinical trial in reconstructive microsurgery.

Timing of Conditioning: Study Design Rationale A key unresolved question concerns the optimal timing of RIC relative to surgery. Two biologically distinct windows of protection have been described: an immediate window (within approximately 1-2 hours of the conditioning stimulus, mediated largely by post-translational protein modifications) and a delayed window (emerging 12*24 hours later, dependent on de novo protein synthesis and gene expression changes). To address this, the trial incorporates three parallel arms: a non-conditioned control group, an immediately preconditioned group (approximately 1 hour before surgery), and a delayed preconditioned group (12-24 hours preoperatively). This design enables direct comparison of both conditioning windows against each other and against standard care.

In cases where intraoperative findings necessitate unplanned revision surgery, a secondary randomization procedure is pre-specified to evaluate the potential benefit of RIC in the setting of threatened flap perfusion.

Intervention Protocol RIC is applied non-invasively to the upper arm using a standard pneumatic tourniquet. Each conditioning session consists of three alternating cycles of 10-minute ischemia (cuff inflated to approximately 250 mmHg, sufficient to occlude arterial inflow) and 10-minute reperfusion (cuff deflated), for a total session duration of 60 minutes. This protocol is consistent with those used in cardiovascular RIC trials and has a well-characterized safety profile.

Microcirculatory Monitoring Postoperative flap perfusion will be continuously assessed using a multimodal approach combining laser Doppler flowmetry and tissue spectrometry (O2C device or equivalent). These complementary techniques enable real-time, non-invasive quantification of microvascular flow, tissue oxygen saturation, and relative hemoglobin concentration. Measurements will be obtained at standardized time points throughout the first five postoperative days, allowing construction of perfusion trajectories and identification of early signs of compromised microcirculation.

Tissue and Biomarker Analyses Standardized biopsies will be obtained from clinically non-essential portions of the flap at defined intraoperative and early postoperative time points. Samples will undergo histological and immunohistochemical evaluation for markers of ischemic injury, cellular stress responses, inflammatory infiltration, and apoptosis. Parallel molecular analyses will characterize expression of proteins and signaling mediators implicated in I/R injury and cytoprotection.

Serial blood samples will be collected perioperatively to quantify circulating biomarkers, including but not limited to markers of oxidative damage, endothelial activation, and systemic inflammatory response. These analyses serve both to detect systemic correlates of local tissue protection and to identify candidate biomarkers for future use in monitoring RIC efficacy.

Clinical Outcome Assessment In addition to mechanistic endpoints, the trial will capture a comprehensive set of clinical outcomes through postoperative day 5 and beyond, including flap survival rate, incidence and severity of wound healing disorders, requirement for revision surgery or re-anastomosis, and total length of inpatient stay. Adverse events and protocol deviations will be systematically recorded.

Statistical Considerations Sample size estimation is based on the primary perfusion endpoint. Randomization will be performed centrally with stratification for relevant clinical variables. All primary analyses will follow the intention-to-treat principle; per-protocol analyses will be conducted as sensitivity analyses.

Significance If RIC is demonstrated to improve perfusion and reduce I/R injury in this setting, it would offer a compelling adjunct to reconstructive microsurgery: it is non-invasive, requires no specialized pharmacology, adds minimal procedural complexity, and is associated with a favorable safety profile in other surgical disciplines. The results of this trial are expected to inform evidence-based guidelines for perioperative conditioning in free flap surgery and to lay the groundwork for larger multicenter investigations.

Being tested
Remote ischemic preconditiong
Keywords
ischemia, reperfusion, free flap, Wound Healing
Medical subject headings
Reperfusion Injury, Ischemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Remote ischemic preconditiongDevice

    The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols.

Study groups in NCT07487220
Study groupRoleWhat they receive
No RIPCNo interventionNo Remote Ischemic Conditioning (RIC) is administered. Participants receive standard perioperative care and undergo free flap reconstruction according to institutional protocols without any preconditioning intervention.
Early RIPCExperimentalRemote Ischemic Conditioning (RIC) is performed 12-24 hours prior to surgery. The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols.
Receives: Device: Remote ischemic preconditiong
Late RIPCExperimentalRemote Ischemic Conditioning (RIC) is performed one hour prior to surgery. The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols.
Receives: Device: Remote ischemic preconditiong

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Microcirculatory perfusion of free flap tissue measured by Laser-Doppler flowmetry and tissue spectrometry

    Continuous assessment of microcirculatory perfusion parameters of free flap tissue using combined Laser-Doppler flowmetry and tissue spectrometry (O2C system). Parameters include blood flow (BF), tissue oxygen saturation (StO₂), and relative hemoglobin concentration (rHb) measured in the transplanted tissue to evaluate the effect of remote ischemic conditioning on flap perfusion and ischemia-reperfusion injury.

    Measured: From intraoperative revascularization until postoperative day 5

Secondary outcomes (2)
  1. Incidence of flap tissue necrosis following free flap reconstruction

    Occurrence and extent of partial or complete flap necrosis following free tissue transfer surgery, assessed clinically during the postoperative observation period.

    Measured: Up to postoperative day 5

  2. Histological markers of vascularization and ischemia-reperfusion injury in flap tissue

    Histological and immunohistochemical analysis of tissue biopsies obtained from the transplanted flap to assess vascularization, cellular damage, inflammatory response, and expression of ischemia-reperfusion related proteins (e.g., HIF1α, VEGF, TNFα, IL-1β). Analyses are performed on intraoperative and postoperative tissue samples to evaluate the biological effects of remote ischemic conditioning.

    Measured: From intraoperative sampling after revascularization until postoperative day 5-7

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Mar 2026
  2. Study start1 Apr 2021
  3. Primary completion31 Dec 2022
  4. Study completion31 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants undergoing free flap reconstruction will be randomly assigned to one of three parallel groups: (1) no remote ischemic conditioning (control), (2) remote ischemic conditioning 12-24 hours prior to surgery, or (3) remote ischemic conditioning immediately prior to surgery. Participants remain in their assigned study arm throughout the study period. In cases of postoperative flap perfusion compromise requiring revision surgery, participants will undergo a secondary randomization to receive either additional remote ischemic conditioning or no conditioning prior to revision.
Masking
None (open label)
Enrolment
49 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07487220
Sponsor's protocol ID
19-6752
Acronym
RIPC
Status last verified
Mar 2021
First submitted
17 Mar 2026
Last updated
25 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data collected in this study will not be made publicly available. All study data will be pseudonymized and stored on secure institutional servers with access restricted to authorized study personnel. Data are collected as part of a single-center clinical study and contain potentially identifiable clinical information. Aggregated results may be published in scientific journals, but individual-level data will not be shared outside the study team in order to protect participant confidentiality.

Publications

  • Drysch M, Fiedler A, Schmidt SV, Reinkemeier F, Puscz F, Kurbacher T, Frey UH, Ochsenfarth C, Lehnhardt M, Wallner C, Sogorski A. Systemic downregulation of EV-associated MiRNAs following remote ischemic preconditioning. Sci Rep. 2025 Dec 11;15(1):43657. doi: 10.1038/s41598-025-31356-9.

    PubMed 41381697
  • Drysch M, Fiedler A, Kurbacher T, Schmidt SV, Reinkemeier F, Puscz F, Becerikli M, Fueth M, Weskamp P, Lehnhardt M, Wallner C, Sogorski A. Ischemia-Reperfusion Injury in Free Flaps: Molecular Mechanisms and Protective Effects of Remote Ischemic Preconditioning. J Cell Mol Med. 2025 Aug;29(15):e70739. doi: 10.1111/jcmm.70739.

    PubMed 40771071

Questions about this trial

What is this clinical trial studying?

A study testing Remote ischemic preconditiong in people with Ischemia-Reperfusion Injury and Free Flap, run by Ruhr University of Bochum at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Microcirculatory perfusion of free flap tissue measured by Laser-Doppler flowmetry and tissue spectrometry (time frame: From intraoperative revascularization until postoperative day 5). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07487220, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in